If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
The rate of unplanned 30-day hospital readmission after discharge is considered a quality measure across U.S. hospitals and impacts Medicare-based reimbursements for inpatient care. Our study objectives were to calculate the 30-day readmission rate to our gynecologic oncology (GON) service, to identify risk factors for readmission, and to determine related costs.
Materials and Methods
All admissions to a high volume, academic GON surgical service during a two-year study period (2013-2014) were queried. Minor surgical procedures were excluded. Patients (pts) requiring hospital readmission within 30 days of discharge were identified. Index admissions were compared for pts with and without readmission. Risk factors and costs of readmission were identified. GI disturbance was defined as high ostomy output, SBO, or ileus. Infection was defined as surgical site infection (SSI) including fever and/or leukocytosis. Data was collected on a diverse array of pt demographic and clinical variables, psychosocial factors and results of an institutional discharge screen survey (Table). Multiple logistic regression was used to identify factors associated with thirty-day readmission.
A total of 1606 women underwent surgical admission to the GON service. A total of 178 readmissions (11.1%) were observed. The average readmission interval was 11.82 days and average length of stay was 5.16 days. The most common reasons for readmission were GI disturbance (43%) and SSI (30%). Factors correlated with readmission included ovarian cancer cytoreductive surgery (OR 2.33, 95% CI 1.23-4.35), creation of an ostomy (OR 7.67, 95% CI 2.99-19.69), and positive discharge screen (OR 3.1, 95% CI 1.48-6.5). The mean cost of each readmission was $25,415; the costs associated with readmission for a GI disturbance were the highest at $32,432. The total inpatient cost related to readmission was $4,523,959.
Readmission to a high volume gynecologic oncology service was most associated with cytoreductive surgery for ovarian cancer, ostomy-related complications and post-discharge complex patient care needs, as identified by institutional discharge screening surveys. The costs of readmission represent a substantial financial burden for hospitals. These data may inform intervention studies to improve the quality of cancer care and reduce health care costs.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS: MaryAnn B. Wilbur: Nothing to disclose; Diana B. Mannschreck: Nothing to disclose; Edward Tanner: Nothing to disclose; Rebecca Stone: Nothing to disclose; Kimberly Levinson: Nothing to disclose; Sarah Temkin: Nothing to disclose; Francis Grumbine: Nothing to disclose; Peter Pronovost: Nothing to disclose; Amanda Fader: Nothing to disclose.